EGFR and non-small cell lung carcinoma: The aim of this study was to investigate the short-term and long-term outcomes and management of patients receiving first-line EGFR-TKI for postoperative recurrence of NSCLC harbouring EGFR gene mutations and to elucidate potential prognostic factors associated with favourable (or poor) survival outcomes in these patients.